NEURO – PET

Dr. Carlos Rugilo y Dr. Gustavo Schuster (*)
Blinded positron emission tomography study of dopamine cell implantation for Parkinson’s disease.
Ann Neurol. 2001; 50:181-7.
20. Karbe H, Holthoff VA, Rudolf J, Herholz K, Heiss WD.
Positron emisión tomography demonstrates frontal cortex and basal ganglia hypometabolism in dystonia.
Neurology. 1992; 42:1540-4.
21. Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR.
The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s disease.
Neurology. 1987; 37:1441-7.
22. Hustinx R, Pourdehnad M, Kaschten B, Alavi A.
PET imaging for differentiating recurrent brain tumor from radiation necrosis.
Radiol Clin North Am. 2005;43:35-47.
23. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al.
Prediction of pathology and survival by FDG PET in gliomas.
J Neurooncol. 2003;64:227-37.
24. Sasaki M, Ichiya Y, Kuwabara Y.
Ringlike uptake of 18-FDG in brain abscess: a PET study.
J Comput Assist Tomogr 1990;14:486-7.
25. Levivier M, Goldman S. Pirotte B.
Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with 18-FDG.
J Neurosurg 1995;82:445-52.
26. Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, et al.
Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations.
J Nucl Med. 2005;46:608-13.
27. Sair HI, Doraiswamy PM, Petrella JR.
In vivo amyloid imaging in Alzheimer’s disease.
Neuroradiology. 2004; 46:93-104.
28. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara m, Shiomi S.
Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.
Ann Nucl Med 2005; 19:677-83.
29. Kim S, Cheng JK, Im SH.
11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.
Eur J Nucl Med Mol Imag 2005;32:52-9.

Leer en formato PDF Imprimir Enviar por email

Email